中证报中证网讯（王珞）天津证监局近日消息，天津多家上市公司积极开展并购重组，今年上半年实施 金额已超百亿元，同比增长65%。"并购六条"发布以来，天津已有6家公司披露开展重大资产重组，多 家本地上市公司成功借助并购重组实现转型升级与提质增效。 强强联合：战略协同产业整合，打造行业新标杆 今年7月，天津证监局联合天津市地方金融管理局、市财政局等7部门发布《天津市支持并购重组若干措 施》，从支持并购重组、集聚并购基金、健全服务体系、强化监管促发展及完善工作机制等方面，构建 形成"五个维度"政策体系，有效打通并优化天津市并购重组的资金链、标的库及交易服务关键环节。 天津普林（002134）电路股份有限公司（以下简称"天津普林"）是北方领先的印制电路板（PCB）制造 商，专注于高精度、高密度、高可靠性PCB产品的研发与生产；泰和电路是同行业内一家在细分市场拥 有深厚技术积累与稳定客户群体的企业。为进一步拓展销售网络、提高产品服务覆盖率与市场占有率， 天津普林通过现金购买资产+增资方式，完成对泰和电路的战略性收购，有效整合产业链优质资源，实 现产品线扩充与技术深度融合。 向"新"而行：顺应时代变革，切换新能源赛道 天津 ...

Group 1 - OpenAI completed a strategic investment round raising $8.3 billion, equivalent to 53.95 billion RMB, to enhance its research and innovation in the AI sector [1] - Inner Mongolia Zhongguang Nuclear announced a strategic investment round raising 11.8 billion RMB, with participation from major firms like China Communications Construction and State Energy Investment [2] - Capitolis secured $56 million, equivalent to 364 million RMB, to expand its stock and foreign exchange business, with investments from Morgan Stanley, JPMorgan, and others [3] Group 2 - MannKind raised $500 million, equivalent to 3.25 billion RMB, from Blackstone to accelerate the development of diabetes treatment products [4] - Uzum completed a Series A funding round of $70 million, equivalent to 4.55 billion RMB, to enhance its digital service ecosystem with investments from Tencent and FinSight Ventures [5][6] - New Sound Semiconductor received a strategic investment of 269 million RMB to strengthen its R&D capabilities in the semiconductor field [7] Group 3 - VITADynamic completed an angel round financing of 300 million RMB, with a post-investment valuation of 1.8 billion RMB, to innovate in the robotics sector [8] - Minghui Pharmaceutical secured $131 million in a Pre-IPO round to expedite product development in oncology and immunology [9] - Fundamental Research Labs raised $33 million in Series A funding to enhance its AI agent technology for gaming [10] - 180 Life Sciences Corp. obtained $425 million in strategic investment to accelerate drug development and clinical projects [11]